Current Study
Bronchiectasis | AIRTIVITY™
The AIRTIVITY™ study is evaluating an investigational oral medication to determine whether it can help reduce flare-ups in people with bronchiectasis. This study is open to adolescents and adults aged 12 years and older who produce sputum and have experienced recent flare-ups. Participants will be randomly assigned (by chance) to receive either BI 1291583 or a placebo tablet taken once daily for up to 18 months. The goal is to better understand whether BI 1291583 can reduce exacerbations, improve symptoms, and provide a new treatment option for people living with bronchiectasis.
Study Status
Closed
Duration
1.5 years
Clinic Visits
10
Phone Check-ins
13
Study Overview
Location
Spearwood
Phase
3
Study Duration
1.5 years
Main Entry Criteria
- People aged 12 years and older
- Must have bronchiectasis
- Must produce sputum (mucus)
- Must have had recent flare-ups (exacerbations)
Participants must be willing to:
- Take 1 tablet daily
- Attend up to 10 clinic visits
- Receive ~13 phone check-ins
- Complete a symptom diary on a smartphone
- Be monitored regularly by study doctors
Main Exclusion Criteria
- A newly diagnosed immune system condition (immunodeficiency) within the past 12 months
- Current or recent lung infections requiring treatment, including:
- Tuberculosis (TB) or non-tuberculous mycobacterial infection
- Allergic bronchopulmonary aspergillosis (ABPA)
- A current chest infection or bronchiectasis flare-up at screening that has not fully resolve
Assessments
At a Glance
Clinic Visits
10
Phone Calls
13
Duration
1.5 years